Skip to Main Content

In its latest bid to defend its franchise product, AbbVie (ABBV) has filed a complaint with the U.S. International Trade Commission in hopes of preventing a would-be rival from selling a lower-cost version of its Humira treatment for rheumatoid arthritis and other ailments.

The drug maker argued that Alvotech, which is seeking a toehold in the U.S. for biosimilar medicines, misappropriated trade secrets and should not be allowed to market its version once it becomes available in the U.S. Alvotech, which is based in Iceland, is awaiting regulatory approval after the U.S. Food and Drug Administration cited pandemic travel restrictions that delayed plant inspections.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment